MetaCap

Syndax Pharmaceuticals Inc. (SNDX)

NASDAQ: SNDXHealth CareBiotechnology: Pharmaceutical PreparationsUSD

8.72-0.41 (-4.49%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

SNDX stock chart

Technical analysis

Key statistics

All statistics
Market cap
$785.05M
EPS (TTM)
-$2.37
52-week range
8.41 – 25.59
Day range
8.69 – 9.27
Volume / Avg
2.18M / 2.63M
Beta
—

52-week range

$8.41$25.59

SNDX stock today

On Nov 20, SNDX ended the session at $8.72, shedding $0.41 (4.49%), versus the S&P 500's 3.70% decline. Shares are 65.9% below their 52-week high of $25.59, set on Mar 25, 2026 and 3.7% above the 52-week low of $8.41, near the bottom of the past year's range. SNDX is down 58.5% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 50.0%.

Syndax Pharmaceuticals has posted a net loss over the last twelve months (EPS of -$2.37), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Syndax Pharmaceuticals

Company profile

Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory R/R acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease. The company is also developing revumenib for the treatment of R/R acute myeloid leukemia (AML) with a nucleophosmin 1 mutation (mNPM1) and in combination with standard-of-care agents in mNPM1 AML or KMT2Ar acute leukemia, as well as for metastatic colorectal cancer; axatilimab to treat idiopathic pulmonary fibrosis; and Entinostat, a Class 1 HDAC inhibitor.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Michael A. Metzger M.B.A.
Headquarters
New York, NY
Employees
298
IPO year
2016
Website
syndax.com

Financial highlights

Full financials

In fiscal 2025, Syndax Pharmaceuticals generated $172.4 million in revenue, up 627.8% from fiscal 2024, its 2nd consecutive year of revenue growth. Syndax Pharmaceuticals reported a net loss of $285.4 million, compared with a loss of $318.8 million a year earlier. Operating margin was -158.4%.

Syndax Pharmaceuticals annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$172.35M$23.68M$0$0$139.71M
Growth+627.84%——-100.00%+9109.56%
Net income$-285.42M$-318.76M$-209.36M$-149.34M$24.93M
EPS (diluted)$-3.29$-3.72$-2.98$-2.46$0.46

Analyst forecast

Forecast

Consensus (12 analysts)

strong_buy

Avg. price target

$35.45+306.54%

  • Strong buy 2
  • Buy 10
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $17.00High $57.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 2, 2026
EPS actual vs est.
$-0.55 vs $-0.52
Surprise
-5.77%

SNDX news

All SNDX news

Syndax Pharmaceuticals peers

Health Care sector
SNDX peer companies
CompanyPrice% ChgMarket capCompare
IRWDIronwood Pharmaceuticals Inc. Class A4.70-0.21%$778.09Mvs SNDX
VSTMVerastem Inc.6.33-7.73%$797.67Mvs SNDX
COLLCollegium Pharmaceutical Inc.24.72-1.94%$768.18Mvs SNDX
ORICOric Pharmaceuticals Inc.7.36-4.42%$764.94Mvs SNDX
RIGLRigel Pharmaceuticals Inc.40.09-2.67%$754.89Mvs SNDX
CRVSCorvus Pharmaceuticals Inc.9.67-3.40%$815.69Mvs SNDX
PHARPharming Group N.V. ADS11.54-5.10%$816.78Mvs SNDX
ARDXArdelyx Inc.2.99-2.29%$751.60Mvs SNDX

Indexes, lists and sector

Syndax Pharmaceuticals stock FAQ

What is Syndax Pharmaceuticals's stock price today?

SNDX last traded at $8.72 as of Nov 20, 4:00 PM EST, down 4.49% on the day. Prices are delayed at least 15 minutes.

Who is Syndax Pharmaceuticals's CEO?

Mr. Michael A. Metzger M.B.A. is the chief executive officer of Syndax Pharmaceuticals Inc., which has about 298 employees.

What is the SNDX 52-week high?

The 52-week high for SNDX is $25.59 and the 52-week low is $8.41. The stock is currently 65.9% below its high.

Compare SNDX